Table 3 A comparison between Rapid (≥ 0.5 mg/dL/day) and Low (< 0.5 mg/dL/day) groups of serum creatinine trajectory during the time-to-nadir

Age (year)

57.4 ± 15.1 (24–77; 53.2–61.6)

61.9 ± 14.2 (23–86; 57.9–65.9)

Gender

 Men

37 (71.2%)

36 (72%)

 Women

15 (28.8%)

14 (28%)

BMI (kg/m²)

24.6 ± 4.8 (17.3–36.9; 23.2–25.9)

24.6 ± 4.9 (16.1–35.9; 23.2–26)

Comorbidity

 Yes

33 (63.5%)

31 (62%)

 No

19 (36.5%)

19 (38%)

Smoking

 Yes

13 (25%)

10 (20%)

 No

39 (75%)

40 (80%)

Pain

 None

23 (44.2%)

24 (48%)

 Right

5 (9.6%)

6 (12%)

 Left

3 (5.8%)

7 (14%)

 Bilateral

21 (40.4%)

13 (26%)

Temperature

37.3 ± 0.5 (36.5–38.8; 37.1–37.4)

37.2 ± 0.5 (36–38.6; 37–37.3)

UOP status at presentation

 Normal

22 (57.89%)

43 (67.19%)

 Low

16 (42.11%)

21 (32.81%)

Tenderness

 Unilateral

4 (36.4%)

3 (50%)

 Bilateral

7 (63.6%)

3 (50%)

Pre-drainage dialysis

 Once

8 (50%)

1 (20%)

 More than once

8 (50%)

4 (80%)

Uremic symptoms

 Yes

16 (30.8%)

13 (26%)

 No

36 (69.2%)

37 (74%)

Mean parenchymal thickness (mm)

13.6 ± 1.6 (9–16; 13.1–14.1)

12.3 ± 2 (8–16; 11.8–12.8)

Pathological type of malignancy

 Bladder cancer

26 (50%)

29 (58%)

 Prostate cancer

3 (5.8%)

7 (14%)

 Colorectal cancer

15 (28.9%)

5 (10%)

 Uterine cervical cancer

6 (11.5%)

8 (16%)

 Lymphoma

2 (3.8%)

1 (2%)

Type of malignancy relative to urinary tract

 Urinary

19 (50%)

46 (71.9%)

 Extraurinary

19 (50%)

18 (28.1%)

Random blood sugar

134.1 ± 62.3 (75–330; 116.8–151.4)

117.3 ± 44.4 (45–280; 104.6–130)

Blood PH

7.36 ± 0.09 (7.15–7.47; 7.34–7.39)

7.37 ± 0.05 (7.23–7.47; 7.367.39)

PCO₂ (mmHg)

24.9 ± 5 (14–36; 23.5–26.3)

24.3 ± 6.3 (15–36; 22.5–26.1)

Acid–base deficit (mmol/L)

− 8.5 ± 5.8 {(− 21)− 1; (− 10.1)–(− 6.9)}

− 8.2 ± 5.3 {(− 20)–1; (− 9.7)–6.7}

HCO₃ (mmol/L)

15.5 ± 4.3 (9–23; 14.3–16.7)

16 ± 4 (6.7–23; 14.8–17.1)

Laterality of drainage

Unilateral

24 (46.2%)

26 (52%)

Bilateral

28 (53.8%)

24 (48%)

SCr at presentation (mg/dL)

7.8 ± 3.4 (2.6–17; 6.9–8.8)

4.7 ± 1.8 (2–9.2; 4.2–5.2)

Post-drainage SCr measures (mg/dL)

SCr at 1st day

6.1 ± 3.2 (1.3–14.8; 5.2–7)

4.4 ± 1.8 (1.7–9; 3.9–4.9)

SCr at 3rd day

4.6 ± 3.2 (0.8–13; 3.7–5.5)

4.1 ± 1.9 (1.2–9.8; 3.5–4.6)

SCr at 5th day

3.2 ± 2.4 (0.6–8.2; 2.5–3.8)

3.5 ± 1.8 (0.9–9.1; 3–4)

SCr at 7th day

2.4 ± 1.9 (0.5–6.5; 1.9–2.9)

3 ± 1.8 (0.5–10.6; 2.5–3.5)

SCr at 10th day

1.9 ± 1.4 (0.3–5; 1.5–2.3)

2.5 ± 1.2 (0.5–5.2; 2.1–2.8)

SCr at 15th day

1.2 ± 0.7 (0.4–2.9; 1–1.4)

1.6 ± 0.68 (0.5–3.9; 1.4–1.7)

SCr at 21st day

1.1 ± 0.6 (0.4–2.5; 1–1.3)

1.5 ± 0.5 (0.5–2.5; 1.3–1.6)

Time-to-nadir SCr (days)

11.3 ± 6 (3–21; 9.7–13)

14 ± 4 (5–21; 12.9–15.1)

SCr normalization rate during 21 days

Normal SCr

37 (71.2%)

21 (42%)

High SCr

15 (28.8%)

29 (58%)

Pus cells in urine after drainage/ HPF

24.9 ± 26.3 (6–100; 17.6–32.2)

33.9 ± 31.1 (3–100; 25–42.7)

SCr-Trs (mg/dL/day)

Mean SCr-Tr during 1st 3 days

1.1 ± 0.6 (0.5–3.3; 0.9–1.3)

0.2 ± 0.2 {(− 1)–0.5; 0.2–0.3)}

Mode of SCr-Tr during 1st 3 days at 0.3 mg/dL/day value

Rapid (≥ 0.3 mg/dL/day)

52 (100%)

17 (34%)

Slow (< 0.3 mg/dL/day)

0 (0%)

33 (66%)

Mode of SCr-Tr during 1st 3 days at 0.7 mg/dL/day value

Rapid (≥ 0.7 mg/dL/day)

37 (71.2%)

0 (0%)

Slow (< 0.7 mg/dL/day)

15 (28.8%)

50 (100%)

Mode of SCr-Tr during 1st 3 days at 1 mg/dL/day value

Rapid (≥ 1 mg/dL/day)

22 (42.3%)

0 (0%)

Slow (< 1 mg/dL/day)

30 (57.7%)

50 (100%)

SCr-Tr during 1st week

0.8 ± 0.4 (0.2–1.7; 0.7–0.9)

0.2 ± 0.2 (− 0.5 to 0.8; 0.2–0.3)

Mean SCr-Tr during time-to-nadir SCr

0.7 ± 0.4 (0.2–2.3; 0.6–0.9)

0.2 ± 0.1 (0–0.8; 0.2–0.3)

Mode of SCr-Tr during time-to-nadir SCr at 0.1 mg/dL/day value

Rapid (≥ 0.1 mg/dL/day)

52 (100%)

47 (94%)

Slow (< 0.1 mg/dL/day)

0 (0%)

3 (6%)

Mode of SCr-Tr during time-to-nadir at 0.3 mg/dl/day value

Rapid (≥ 0.3 mg/dL/day)

48 (92.31%)

16 (32.0%)

Slow (< 0.3 mg/dL/day)

4 (7.69%)

34 (68.0%)

Mode of SCr-Tr during time-to-nadir SCr at 0.5 mg/dl/day value

Rapid (≥ 0.5 mg/dL/day)

37 (71.15%)

1 (2.0%)

Slow (< 0.5 mg/dL/day)

15 (28.85%)

49 (98.0%)

SCr-Tr during 1st 3 days-SCr-Tr during 1st week (mg/dL/day)

0.3 ± 0.5 (− 0.37 to 1.7; 0.2–0.5)

− 0.03 ± 0.2 (− 1.3 to 0.2; − 0.1 to 0.04)

SCr-Tr during 1st 3 days–SCr-Tr during time-to-nadir (mg/dL/day)

0.4 ± 0.5 (− 0.3 to 1.6; 0.2–0.5)

− 0.04 ± 0.3 (− 1.3 to 0.3; − 0.1 to 0.04)